Antipsychotics - History of development and field of indication, new wine - Old glassess

Psychiatria Danubina

Volumn 24, Issue SUPPL.3, 2012, Pages 342-344

  Jašović Gašic, Miroslava ^a,b   Vuković, Olivera ^a,c   Pantović, Maja ^c   Cvetić, Tijana ^c   Marić Bojović, Nadja ^a,c  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b Serbian Medical Society   (Serbia)

^c CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

Antipsychotics; History; Indication

Indexed keywords

CHLORPROMAZINE; DOPAMINE 2 RECEPTOR; HISTAMINE; LEPTIN; NEUROLEPTIC AGENT; SEROTONIN;

AGGRESSION; ANXIETY; BRAIN REGION; CLINICAL PRACTICE; CONFERENCE PAPER; DEPRESSION; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HOSTILITY; HUMAN; HYPOTHALAMUS; MENTAL DISEASE; NEUROTRANSMISSION; PEPTIDERGIC NERVOUS SYSTEM; QUALITY OF LIFE; SCHIZOPHRENIA; THINKING IMPAIRMENT; WEIGHT GAIN; ANIMAL; ARTICLE; COMORBIDITY; HISTORY; PSYCHIATRY;

ANIMALS; ANTIPSYCHOTIC AGENTS; COMORBIDITY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; PSYCHIATRY;

EID: 84872827739     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (13)

1. Alexander GC, Gallagher SA, Mascola A et al. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiology and Drug Safety (2011) DOI: 10.1002/pds
2. Divac N, Marie NP, Damjanovic A et al. Use or underuse of therapeutic guidelines in psychiatry? Psychiatr Danub 2009;21:224-9.
3. Doknić M, Marić N, Damjanović A et al. Uloga antipsihotika u promeni telesne težine i metaboličkog statusa. Acta Clinica 2007;7:173-179.
4. Jasovic-Gasic M, Marie N, Doknic M et al. Metabolic annd neuroendocrine effects of long-acting injectable risperidone in reallife conditions. Eur Psychiatr 2010;25(Suppl 1):P03-341
5. Jasovic-Gasic M, Marie N. Risperidon vs. other antipsychotics in schizophrenia: The assesment of patient attitudes. Psychiatr Danub 2004;16:127-31.
6. Jasovic-Gasic M, Crnobaric C, Miljevic C et al. Clozapine in the treatment of depressive syndrome in schizophrenia. Biol Psychiatry 1997;42(Suppl 1):170S.
7. Jasovic-Gasic M, Miljevic C, Crnobaric C. Antidepressants versus clozapine in the treatment of depressive syndrome in schizophrenia. Eur Neuropsychopharmacol 1997;7(Suppl 2):S272.
8. Jasovic-Gasic M, Crnobaric C, Miljevic C et al. Efficacy of Clozapine therapy in aggression. Eur Psychiatry 1998;13(Suppl 4):314S.
9. Paunovic RV, Jasovic-Gasic M, Bogdanovic M et al. Clozapine in the treatment of negative symptoms in schizophrenia. Ibid 1, Psychopharmacology 1988; Suppl. to Voi 96:344.
10. Jasovic-Gasic M, Marie N, Damjanovic A. Risperidone liquid in psychotic disorders-efficacy and attitudes. Psychiatr Danub 2005;17:191-6.
11. Marinkovic D, Totic S, Jasovic-Gasic M et al. Clozapine is efficient in long term treatment of negative syndrome, but no cognitive functioning, in schizophrenia? A three-tear follow-up study. Eur Neuropsychopharmacol 2000;10(Suppl 3):321.
12. Popovic V, Doknic M, Marie N et al. Changes in Neuroendocrine and Metabolic Hormones Induced by Atypical Antipsychotics in Normal-Weight Patients with Schizophrenia. Neuroendocrinology 2007;85:249-56.
13. Weiss E, Hummer M, Koller D et al. Off-label use of antipsychotic drugs. J Clin Psychopharmacol 2000;20:695-8.